Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Careful patient selection may reduce risk

LEARN MORE

Safety and tolerability

WinRho has a safety and tolerability profile established in clinical trials and more than 15 years of use

In clinical trials, 7% of WinRho* infusions had at least one adverse reaction1

  1. – The most common adverse reactions were: headache (2%), chills (<2%) and fever (1%), which are expected adverse drug reactions following intravenous administration of human immune globulins1

* Studies performed using WinRho/WinRho SD

Labeling revision and the risk of intravascular hemolysis (IVH)

Labeling was revised as a result of safety signals derived from an analysis of the WinRho postmarketing safety surveillance database

  1. – Cangene has received safety reports on WinRho use over the past 15 years

  1. – The estimated reporting rate of IVH and its potential complications has not increased since the first published reports2

Estimated frequency of hemoglobinemia and/or hemoglobinuria following administration of anti-D for immune thrombocytopenic purpura (ITP)3

Safety tolerability

Disseminated intravascular coagulation (DIC), which is a serious reported complication of IVH, is very rare4

WinRho SDF Liquid is Bioequivalent to WinRho SDF Lyophilized1

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on the area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similar elimination half-lives. WinRho SDF must be administered via the intravenous route for the treatment of ITP.

important risk information

WARNING: INTRAVASCULAR HEMOLYSIS (IVH)
Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF.

IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS).

Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported.

Closely monitor patients treated with WinRho® SDF for ITP in a healthcare setting for at least eight hours after administration. Perform a dipstick urinalysis at baseline, 2 hours and 4 hours after administration and prior to the end of the monitoring period. Alert patients and monitor the signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms of IVH within eight hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or suspected after WinRho administration post-treatment laboratory tests should be performed including plasma hemoglobin, haptoglobin, LDH and plasma bilirubin (direct and indirect).

Please see full Important Risk Information for more detailed risk information
Please see WinRho SDF Prescribing Information for full prescribing details

References. 1. WinRho SDF prescribing information, March 2010. 2. Data on file, Cangene Corporation. 3. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood.2000:95:2523-2529. 4. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532-1537.